文献速递胰腺与胆道疾病

上市后报告的埃卢卡多林相关胰腺炎病例:伴或不伴胆囊患者

Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder.
PubMed 文献 · Aliment Pharmacol Ther · 2018-01-19

该研究回顾性分析了2015年5月27日至2017年2月15日FAERS数据库中119例埃卢卡多林相关胰腺炎报告。其中1例死亡、75例住院;47例在首次或第二次给药后发生胰腺炎,中位起病时间1天(范围1-56天)。无胆囊患者虽接受推荐的低剂量75 mg并筛查酒精滥用,但在胰腺炎病例中似乎占比过高。

要点

  • FAERS数据库119例埃卢卡多林相关胰腺炎中1例死亡、75例住院。
  • 47例在首次或第二次给药后发生胰腺炎,中位起病时间1天(范围1-56天)。
  • 无胆囊患者虽用推荐低剂量75 mg并筛查酒精滥用,在病例中似乎占比过高。

核心结论

  • FAERS病例提示伴或不伴胆囊的患者使用埃卢卡多林均有发生胰腺炎的风险。
  • 无胆囊患者尽管接受推荐的低剂量埃卢卡多林75 mg并筛查酒精滥用,在发生埃卢卡多林相关胰腺炎的患者中似乎占比过高。

研究设计与样本

  • 回顾性分析2015年5月27日至2017年2月15日向FDA不良事件报告系统(FAERS)数据库报告的所有美国埃卢卡多林相关胰腺炎不良事件报告。
  • 分析纳入119例埃卢卡多林相关胰腺炎病例。

主要发现

  • 119例中1例死亡、75例住院。
  • 67例报告了患者胆囊存在(n=12)或缺失(n=55)。
  • 55例无胆囊患者接受的埃卢卡多林剂量为75 mg(n=43)、100 mg(n=5)或未报告(n=7)。
  • 119例中37例报告患者不滥用酒精,82例未报告酒精滥用状态。
  • 唯一死亡病例为无胆囊患者,接受埃卢卡多林75 mg且不滥用酒精。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cases of pancreatitis were identified in the eluxadoline clinical development program, reflected in initial product labelling, and the subject of postmarketing reports. AIM: To analyse postmarketing cases of eluxadoline-associated pancreatitis. METHODS: We retrospectively analysed all US adverse event reports of pancreatitis associated with eluxadoline reported to the FDA Adverse Event Reporting System (FAERS) database from May 27, 2015 through February 15, 2017. RESULTS: The analysis included 119 cases of pancreatitis associated with eluxadoline; one resulted in death and 75 in hospitalisation. Sixty-seven cases reported the presence (n = 12) or absence (n = 55) of the patient's gallbladder. The eluxadoline dose received in the 55 cases of patients without gallbladders was 75 mg (n = 43), 100 mg (n = 5), or not reported (n = 7). Of the 119 cases, 37 reported the patient did not abuse alcohol and 82 did not report the alcohol abuse status. The single fatal case occurred in a patient without a gallbladder who received eluxadoline 75 mg and did not abuse alcohol. Forty-seven cases reported development of pancreatitis within the first or second dose of eluxadoline initiation. The median time to onset for the development of pancreatitis (n = 83) was 1 day, ranging from 1 to 56 days of continued use of eluxadoline. CONCLUSION: The FAERS cases suggest that patients with or without a gallbladder receiving eluxadoline are at risk for the development of pancreatitis. However, patients without a gallbladder, despite receiving the recommended lower dose of eluxadoline 75 mg and screening for alcohol abuse, appear to be overrepresented among patients who developed eluxadoline-associated pancreatitis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Harinstein L, Wu E, Brinker A, et al. Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder. Aliment Pharmacol Ther. 2018. PMID: 29349789. doi:10.1111/apt.14504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。